Barcelona, Spain

Elena Cubero Jordà

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2021-2023

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Elena Cubero Jordà

Introduction

Elena Cubero Jordà is a prominent inventor based in Barcelona, Spain. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for the treatment of lysosomal storage diseases and other related disorders. With a total of three patents to her name, her work is paving the way for new therapeutic options.

Latest Patents

Elena's latest patents include innovative compounds and methods that address critical health issues. One of her notable patents focuses on heteroaryl compounds and their use in treating lysosomal storage diseases, such as Gaucher's disease. This application details compounds of a specific formula and their salts and solvates, along with methods for their preparation and pharmaceutical compositions. Another significant patent involves isoquinoline compounds, which are aimed at conditions associated with the alteration of beta-galactosidase activity. This patent outlines the compounds' therapeutic uses, particularly for GM1 gangliosidoses and Morquio syndrome, type B.

Career Highlights

Elena Cubero Jordà is currently associated with Minoryx Therapeutics S.L., where she continues to innovate and develop new therapeutic solutions. Her work is characterized by a strong focus on addressing complex medical conditions through chemical innovation.

Collaborations

Elena collaborates with esteemed colleagues, including Ana Maria García Collazo and Xavier Barril Alonso, who contribute to her research and development efforts.

Conclusion

Elena Cubero Jordà's contributions to pharmaceutical chemistry are noteworthy, as she continues to develop innovative solutions for serious health conditions. Her patents reflect her commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…